Explore Dexcom's Q2 2025 financial report highlighting 15.2% revenue growth and a $750M share repurchase plan. A compelling buy for investors in the CGM market.
Explore Dexcom's latest Form 8-K filing detailing significant corporate updates and stock info as of July 25, 2025. Stay informed on DXCM's market activities.
Explore Dexcom, Inc.'s 8-K report detailing significant events and stock performance as of May 9, 2025. Get insights on DXCM and corporate developments impacting investors.
Explore Dexcom, Inc.'s recent 8-K/A filing detailing critical updates from March 6, 2025, vital for investors and market analysts.
Explore Dexcom, Inc.'s latest 8-K report filed on May 8, 2025, revealing vital updates in the medical tech sector. Stay informed on significant events affecting DXCM stock.
Explore Dexcom, Inc.'s latest 8-K filing details, stock info, and significant updates for May 1, 2025. Essential for investors and stakeholders.
Explore Dexcom's Q1 2025 financial performance with a 12.5% revenue growth but declining net income. Key insights for investors on profitability and future strategies.
Explore Dexcom, Inc.'s 8-K report filed on May 1, 2025, detailing company info, stock data, and compliance with SEC regulations.
Explore Dexcom, Inc.'s 8-K report filed on March 21, 2025, detailing crucial updates for stakeholders. Stay informed about stock details, compliance, and significant company events.
Explore DexCom, Inc.'s latest 8-K filing with the SEC detailing significant updates. Ticker: DXCM, NASDAQ.
Explore DexCom, Inc.'s significant 8-K filing revealing crucial shareholder updates. Stay informed on market events affecting DXCM stock performance.
Explore DexCom, Inc.'s 2024 financial report showcasing impressive revenue growth, effective cost management, and strategic R&D investments in the diabetes management market.